Evaluation of Memantin in preservation of neurocognition with craniospinal irradiation.

Memantine to preserve memory and neurocognition following craniospinal irradiation (MEMENTO)- A randomised control trial - MEMENTO

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062273

Enrollment

101

Registered

2024-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G938- Other specified disorders of brain

Interventions

Intervention1: MEMANTINE- 5mg once daily at bed time for 1 week then 5mg twice daily for 1 week then 10mg twice daily for 6 months: Memantine is an uncompetitive N-Methyl D-Aspartate receptor antagoni

Eligibility

Inclusion criteria

Inclusion criteria: Planned for CSI, with or without boost dose with or without systemic chemotherapy Informed consent or assent taken Karnofsky Performance Status, Lanksy Performance Status=60

Exclusion criteria

Exclusion criteria: Re-irradiation Prior exposure to memantine Inability to undergo Wechsler test

Design outcomes

Primary

Measure	Time frame
Cognitive-deterioration-free survivalTimepoint: 2yrs after accrual	—

Secondary

Measure	Time frame
Overall survival (OS)Timepoint: at the completion of the study;Progression free survival (PFS)Timepoint: until progression at any time point during the study	—

Countries

India

Contacts

Public ContactDr Tejpal Gupta

Tata Memorial Hospital

tejpalgupta@rediffmail.com9821548980

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026